Autologous Stromal Vascular Fraction in Treatment of Male Androgenic Alopecia
ConditionAndrogenic Alopecia
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18-55
SponsorSohag University
About this trial
Evaluation of Safety and efficacy of autologous stromal vascular fraction derived from denovo versus platelet rich plasma enhanced donner site in treatment of male androgenic alopecia
Eligibility criteria
Qualifiers
Male patients with androgenic alopecia
Disqualifiers
Patients with other hair loss disorders as telogen effluvium, anagen effluvium, alopecia areata, cicatricial alopecia and trichotillomania.
Trial design
Treatments tested in this trial
- autologous stromal vascular fraction
Treatment groups
40 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov